Literature DB >> 22258813

A case of cervical multicentric Castleman disease treated with intensity-modulated radiation therapy using helical tomotherapy.

Natsuo Tomita1, Takeshi Kodaira, Takuya Tomoda, Kosei Nakajima, Takayuki Murao, Kunio Kitamura.   

Abstract

Castleman disease (CD) is a rare lymphoproliferative disorder. Two clinical entities are described: a unicentric form with disease confined to a single lymph node region and a multicentric form characterized by generalized lymphadenopathy and systemic symptoms. Although surgery is regarded as standard therapy for the unicentric form, no consensus has been reached concerning the standard treatment for multicentric CD. We report here a case of cervical multicentric CD treated with intensity-modulated radiation therapy (IMRT), using helical tomotherapy to minimize xerostomia in comparison with conventional radiotherapy. A 29-year-old woman complained of neck swelling. Computed tomography showed lymphadenopathy in both sides of the neck. The patient was diagnosed with the plasma cell subtype of CD on biopsy. After initial treatment with prednisone, IMRT was planned to avoid normal structures, for example the parotid gland. The cervical lymphadenopathy shrank gradually during IMRT with 44 Gy in 22 fractions. Four years and 3 months after IMRT, regrowth of cervical lymph nodes has not been detected. The parotid function improved dramatically on quantitative salivary scintigraphy between 3 and 12 months after IMRT. Radiotherapy could be an option for multicentric CD, and IMRT is an effective means of minimizing xerostomia in head and neck lesions.

Entities:  

Mesh:

Year:  2012        PMID: 22258813     DOI: 10.1007/s11604-012-0052-0

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  10 in total

1.  Intensity modulated radiation therapy (IMRT): a new promising technology in radiation oncology.

Authors:  B S Teh; S Y Woo; E B Butler
Journal:  Oncologist       Date:  1999

2.  Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot.

Authors:  B CASTLEMAN; V W TOWNE
Journal:  N Engl J Med       Date:  1954-09-02       Impact factor: 91.245

3.  Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations.

Authors:  A R Keller; L Hochholzer; B Castleman
Journal:  Cancer       Date:  1972-03       Impact factor: 6.860

4.  Treatment planning constraints to avoid xerostomia in head-and-neck radiotherapy: an independent test of QUANTEC criteria using a prospectively collected dataset.

Authors:  Vitali Moiseenko; Jonn Wu; Allan Hovan; Ziad Saleh; Aditya Apte; Joseph O Deasy; Stephen Harrow; Carman Rabuka; Adam Muggli; Anna Thompson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-02       Impact factor: 7.038

5.  Adaptive radiotherapy for head-and-neck cancer: initial clinical outcomes from a prospective trial.

Authors:  David L Schwartz; Adam S Garden; Jimmy Thomas; Yipei Chen; Yongbin Zhang; Jan Lewin; Mark S Chambers; Lei Dong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-02       Impact factor: 7.038

6.  Clinical Features and Outcome in HIV-Associated Multicentric Castleman's Disease.

Authors:  Mark Bower; Tom Newsom-Davis; Kikkeri Naresh; Shairoz Merchant; Belinda Lee; Brian Gazzard; Justin Stebbing; Mark Nelson
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

Review 7.  Neoadjuvant radiotherapy of primary irresectable unicentric Castleman's disease: a case report and review of the literature.

Authors:  Iris A C de Vries; Marjolein M S van Acht; Thomas B J Demeyere; Marnix L M Lybeert; Jean-Paul de Zoete; Grard A P Nieuwenhuijzen
Journal:  Radiat Oncol       Date:  2010-02-02       Impact factor: 3.481

8.  Aichi cancer center initial experience of intensity modulated radiation therapy for nasopharyngeal cancer using helical tomotherapy.

Authors:  Takeshi Kodaira; Natsuo Tomita; Hiroyuki Tachibana; Tatsuya Nakamura; Rie Nakahara; Haruo Inokuchi; Nobukazu Fuwa
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-14       Impact factor: 7.038

Review 9.  Angiofollicular lymph node hyperplasia (Castleman's disease).

Authors:  M J McCarty; S J Vukelja; P M Banks; R B Weiss
Journal:  Cancer Treat Rev       Date:  1995-07       Impact factor: 12.111

Review 10.  Treatment of Castleman's disease.

Authors:  Angela Dispenzieri; Morie A Gertz
Journal:  Curr Treat Options Oncol       Date:  2005-05
  10 in total
  4 in total

1.  Castleman disease of the parapharyngeal space: Diagnosis and management.

Authors:  S Jbali; S Zarraa; A Hadhri; G E F Noubbigh; S Yahyaoui; C Nasr
Journal:  Int J Surg Case Rep       Date:  2022-09-05

2.  Radiotherapy for a rare phosphaturic mesenchymal tumor in the middle ear presenting with oncogenic osteomalacia: A case report.

Authors:  Taiki Takaoka; Natsuo Tomita; Yoji Shido; Satoshi Baba; Mayu Fukushima; Chikao Sugie; Yuta Shibamoto
Journal:  Medicine (Baltimore)       Date:  2021-09-24       Impact factor: 1.817

Review 3.  Comprehensive analysis of 225 Castleman's diseases in the oral maxillofacial and neck region: a rare disease revisited.

Authors:  Xiaotong He; Qiong Wang; Yaping Wu; Jiaan Hu; Dongmiao Wang; Bin Qi; Wei Zhang; Yanling Wang; Jie Cheng
Journal:  Clin Oral Investig       Date:  2017-10-04       Impact factor: 3.573

4.  Castleman's Disease Presenting as a Parotid Mass in the Pediatric Population: A Report of 2 Cases.

Authors:  Sean W Delaney; Shengmei Zhou; Dennis Maceri
Journal:  Case Rep Otolaryngol       Date:  2015-10-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.